Member Info for aj242

An encouraging RNS ONLY if it was the research required for the Asia deal to occur. Otherwise it’s not telling us much we didn’t know but does reaffirm what we thought in another pre clinical model which is nice.

Can’t see much movement in SP, maybe 3-3.2?

Hello £1.70 mark. Problem with BOO is they have enemies in the press (some may say rightfully so), it will never get to the heights it should because every 4-6 months there’s a big story that drops it back down to £2.

I think people must remember that the safety and efficacy data must be significant enough for bodies to reimburse the drug, otherwise it will only be used in private practice. Just because its a "bit better" may not be enough for NICE and the SMC to say ok we will pay for that.

However, I don't think this will be an issue, just to keep in mind.

I would assume so, I don't see avacta having a medical affairs department and aren't recruiting for one. With there only being a need for phase II trial to gain MA, one would expect a medical team in place to start building relationships with therapy area experts, congress support, insight gathering etc..

Regarding your last point, what I would say is that the vasculature of mice and humans can be quite different in different tumour sites, so the seeping of drug once tumour shrinkage occurs may pose a risk.

No I don't think it is

Agree with this. The lack of requirement for a phase III is very positive. In regards to funding, I don't suspect that to be an issue. For me it is all about whether the precision technology can be replicated in humans. There are plenty of technologies out there which work great in mice but can be hard to replicate in humans with safety being the key concern. We don't know how the human immune system will react, nor we do we know about the potential of anti-drug antibodies for this molecule and the impact of them.

A lot resides on the results of the phase I, if negative, will probably set the company back a couple of years, if positive, I honestly believe the company will be utterly transformed.

What I don't know much about is the prospect of another company aquiring the rights to their technology or buying the company out completely. I can't see why big pharma would want such a competitior if the tech works

Chab, lets be realistic. Its highly likely to be mainly a repetition of information we already know with no fixed timescales.

Definitely Jay. Another thing people haven't yet grasped is the regulatory nightmare that is submitting to the EMA, or now, MHRA and getting reimbursement through NICE/SMC. This is a very long process so if we can streamline this then brilliant!

What an absolutely brilliant interview. Given my background in oncology, I am extremely excited about the Phase I results and possible expansion from chemotherapies into immunotherapies. Many won't grasp the magnitude of the potential there is here, heavily based on this trial. Forget the antigen test, this company is ALL about the precision tech. The quicker people understand that the better.

totally agree yuyus. 9p+ should be achievable on the right RNS. My worry is that there are plenty of PI's who will definitely sell into any rise, inhibiting the true rise this could achieve.

I’ve been on this board for over 2 years deejay lol....bore off!

What astounds me each day is to read posts on LSE boards from people like deejay trolling. Imagine being a grown person causing arguments and sending insults on the internet under an alias. It’s quite a sad state of affairs.

Deejay, who the hell are you? Jay is most definitely not a troll. He’s been here for years although his hey ho posts do get a bit annoying. Nonetheless, he’s been an informative poster, as have all the other regulars here, even if I think some are a bit deluded at times they all want the best for the company and their investment.

Bore off

ahhh what have I missed today, board is popping.

This must be the post of the day hahahaha. Weekends on LSE are always full of absolute garbage

Looks like the board has gone to shet for the weekend, swamped with derampers and people I’ve never seen post here. Standard.

See you all on Monday at the 220 open ;)

A lot of people saying £5 by summer. I genuinely think this will reach that price on the news of the first contract being awarded come April. Don't underestimate the power of PI drive covid shares, we have seen what has happened with a few others already. £5 come April and then a steady rise towards 7/8 over the summer imo. Then we find out about the phase I trial...

So Merchant, like I have always said, AVCT and ODX will work together. Instead of ****ging avct off, you should now be grateful.

WHERE ARE YOU SON